Empagliflozin Goes Off-Patent: Affordable Diabetes Treatment and Connex Pharma’s Role in the Supply Chain
The pharmaceutical landscape has witnessed a significant shift with the patent expiration of Empagliflozin, a widely prescribed diabetes medication originally developed by Boehringer Ingelheim (BI) under the brand name Jardiance. With the entry of generic versions from leading domestic drugmakers, the price of Empagliflozin has plummeted by 80-90%, making it more accessible to millions of diabetes patients in India.
The Impact of Generics on Affordability
On March 11, when Empagliflozin’s patent protection ended, major pharmaceutical companies such as Alkem, Glenmark, and Mankind Pharma swiftly launched their own versions of the drug. This has resulted in a drastic reduction in price, bringing the cost of a 10 mg tablet down from ₹59 to approximately ₹5.50. With over 100 million people affected by diabetes in India, this move is expected to enhance access to an effective treatment that was previously considered costly by many patients.
Connex Pharma: Supporting the Supply Chain with Key Raw Materials
As the pharmaceutical industry adapts to these changes, Connex Pharma plays a crucial role in the production of Empagliflozin by manufacturing and supplying Trimethylchlorosilane, a key raw material in the synthesis of this vital API. Our commitment to providing high-quality raw materials ensures a steady and reliable supply for pharmaceutical companies producing Empagliflozin, ultimately supporting the availability of affordable diabetes medication in the market.
Innovations in Generic Drug Manufacturing
Apart from price reductions, pharmaceutical companies are introducing innovations to enhance patient safety and education. Alkem Laboratories, for instance, has implemented anti-counterfeit security bands on its Empagliflozin packaging, along with QR codes offering detailed prescribing information in multiple languages. Glenmark, meanwhile, has introduced various fixed-dose combinations of Empagliflozin with Linagliptin and Metformin to provide comprehensive treatment options for diabetes patients with cardiovascular risks.
A Step Forward in Diabetes Management
The availability of cost-effective generic Empagliflozin is expected to improve diabetes management in India, where treatment expenses are often borne out-of-pocket. With more pharmaceutical firms expected to launch their versions of the drug, patients and healthcare professionals will benefit from increased choices and accessibility.
At Connex Pharma, we take pride in our contribution to the pharmaceutical ecosystem, ensuring a seamless supply of essential raw materials for drug manufacturing. As the industry progresses, we remain committed to supporting innovation and affordability in healthcare solutions.
